Efficacy and safety of irinotecan after chemotherapy in combination with immunotherapy in patients with extensive stage small cell lung cancer: a phase II trial - Efficacy and safety of irinotecan after chemotherapy in combination with immunotherapy in patients with extensive stage small cell lung cancer: a phase II trial

Third department of internal medicine, Universtiy of Fukui0 个研究点目标入组 22 人开始时间: 2021年1月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who previously treated with irinotecan 2) Patients with homozygous polymorphisms for UGT1A1*28 and *6 (*28/*28, *6/*6, and *6/*28) 3) Diarrhea (grade 1 or more) before the treatment. 4) Uncontrolable pleural or pericardial effusion. 5) Within 2 weeks after radiotherapy. 6) Operation within 4 weeks. 7) Active double cancer. 8) Active infectious disease. 9) Severe complications including heart failure, hepatic failure, renal failure, paresis of intestine, and ileus. 10) Pregnant woman. 11) HBs antigen positive. 12) Patients who received systemic corticosteroid (10mg or more prednisolone conversion). 13) The subjects whom the doctor excluded.

发起方

Third department of internal medicine, Universtiy of Fukui